1. Home
  2. YORW vs ADCT Comparison

YORW vs ADCT Comparison

Compare YORW & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo York Water Company (The)

YORW

York Water Company (The)

HOLD

Current Price

$31.05

Market Cap

472.0M

Sector

Utilities

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.88

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YORW
ADCT
Founded
1816
2011
Country
United States
Switzerland
Employees
104
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
472.0M
484.4M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
YORW
ADCT
Price
$31.05
$4.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
71.8K
875.6K
Earning Date
06-08-2026
05-25-2026
Dividend Yield
2.94%
N/A
EPS Growth
N/A
30.86
EPS
1.39
N/A
Revenue
$77,488,000.00
$81,357,000.00
Revenue This Year
$14.53
$1.15
Revenue Next Year
$5.77
$86.93
P/E Ratio
$22.35
N/A
Revenue Growth
3.37
14.85
52 Week Low
$29.68
$1.05
52 Week High
$36.48
$4.98

Technical Indicators

Market Signals
Indicator
YORW
ADCT
Relative Strength Index (RSI) 31.75 69.79
Support Level $30.02 $3.25
Resistance Level $32.98 N/A
Average True Range (ATR) 0.64 0.27
MACD -0.19 0.05
Stochastic Oscillator 6.60 90.38

Price Performance

Historical Comparison
YORW
ADCT

About YORW York Water Company (The)

The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: